Ferring Signs an Exclusive License Agreement with Invo for its INVOcell Intravaginal Culture (IVC) System in the US
Shots:
- Ferring to receive the US commercialization rights for INVOcell Technology and Invo will take care of its manufacturing and supplying activities for Ferring
- Invo has rights to establish INVO clinics for exclusive commercialization of INVOcell outside the US. The agreement is expected to close in Jan- 2019
- INVOcell is a novel technology with small polystyrene capsule- used for the treatment of infertility in women and received the US FDA approval in 2015
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
